Automate Your Wheel Strategy on BVS
With Tiblio's Option Bot, you can configure your own wheel strategy including BVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BVS
- Rev/Share 8.6004
- Book/Share 2.8099
- PB 2.9809
- Debt/Equity 2.3351
- CurrentRatio 1.427
- ROIC -0.0195
- MktCap 443932344.0
- FreeCF/Share 0.3625
- PFCF 18.5528
- PE -13.9706
- Debt/Assets 0.5003
- DivYield 0
- ROE -0.2122
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BVS | JP Morgan | Underweight | Neutral | $12 | $13 | Dec. 17, 2024 |
News
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
Read More
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.
Read More
Bioventus Reports First Quarter Financial Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.
Read More
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.
Read More
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Read More
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Read More
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Published: March 11, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
Read More
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
Read More
About Bioventus Inc. (BVS)
- IPO Date 2021-02-11
- Website https://www.bioventus.com
- Industry Medical - Devices
- CEO Robert E. Claypoole
- Employees 930